

In vaginal candidosis:

TRADEMARK

The elegant way to treat an inelegant problem



ABC update – three new editions




Just published


As any general practitioner knows, diseases of the ear, nose and throat are some of the most common complaints that bring patients to the surgery – children suffering misery and discomfort and adults having to take time off work. In the second, revised edition of ABC of Ear, Nose and Throat Harold Ludman gives busy clinicians expert, up to date advice on assessing and managing these conditions.

Price: Inland £5.95; Abroad £7.50; USA\$14.00 BMA members: Inland £5.45; Abroad £7.00; USA\$13.00

One of today's most pressing medical and social problems is comprehensively reviewed in the ABC of Alcohol. With an extended introduction by Richard Smith, assistant editor of the BMJ, this second, revised and expanded edition brings readers up to date on current approaches to the diagnosis and treatment of alcoholism. Essential reading for all doctors who need to understand the appalling difficulties that this condition creates for patients and their families – and indeed for doctors themselves.

Price: Inland £5.95; Abroad £7.50; USA\$13.00 BMA members: Inland £5.45; Abroad £7.00; USA\$12.00





Many advances in the treatment of diabetes have been made in the past decade: self measurement of blood glucose, intravenous infusions and intramuscular insulin treatment for diabetic emergencies, continuous subcutaneous insulin infusion techniques, and new tests for autonomic function. The outlook for diabetic pregnancy has been transformed; photocoagulation for retinopathy is reducing blindness; and at last diabetic renal disease is receiving some attention. Dr Peter Watkin's articles set these advances in their clinical context, providing a practical guide to the management of diabetes for non-specialist doctors and nurses. There have already been several more developments both in understanding the causes of diabetes and improving its management, and this second, revised, edition incorporates the most important of these latest innovations.

Price: Inland £4.95; Abroad £6.50; USA\$11.00 BMA members: Inland £4.45; Abroad £6.00; USA\$10.00

All prices include postage by air abroad

ORDER FORM		RITISH MEDICAL JOURNAL, P.O. Box 295, and or any leading medical bookseller.
Please send me the following books:		
		☐ I encloseBMA Membership No
	•	Please make cheques payable to to British Medical Journal or debit my credit card (<i>please tick box</i>)
		Access Visa American Express
Name		Card No.
Address		Card expiry date
		Signature
		☐ Please send me a book catalogue

Adalast The cardioprotective corons by the rapeutic agent



Composition: 1 Adalat capsule centains 10 mg nitedipine. Indications: 1. Coronary heard disease: Chronic stable angina pectoris, angina at rest, including vaso-spastic angina (Prinzmetal's angina, variant angina) and unstable angina (crescendo preinfarction angina), angina pectoris following myocardial infarction (except in the first 8 days following acute myocardial infarction).

2. Hypertension. Contraindications: Hypersensitivity to Adalat and the whole period of pregnancy. There are no findings on use during lactation. Caution should be exercised in the presence of pronounced low blood pressure (severe hypotension: systolic blood pressure < 90 mmHg). Cardio-vascular shock. Side-effects: Side-effects generally occur at the start of therapy and are often of a slight and transient nature: facial flush, heat sensation, headache. In isolated cases, particularly at higher doses: nauses dizziness, tiredness, skin reactions, paraesthesia, hypotensive reaction, palpitations and increased pulse rate. Occasionally leg oedema due to dilatation of the blood vessels. Extremely rare: during long-term therapy, gingival hyperplasia which regresses completely once therapy is discontinued; chest pain (which may be angina pectoris-like pain) – where this occurs and a causal connection with Adalat is suspected, therapy should be discontinued. Caution should be exercised in dialysis patients with malignant hyperplasia with reversible renal failure with hypovolaemia, since vasodilatation can result in a reduction in blood pressure. Treatment of

hypertension with this drug requires regular medical supervision. Individuals may react differently to this drug and some patients' ability to drive and to operate machinery may be impaired. This applies particularly at the start of treatment, when changing from one preparation to another and if alcoholis consumed. Mode of action: Adalat is a calcium antagonist and is classified as a coronary therapeutic agent/antihypertensive agent. <u>Dosage:</u> Treatment should be adapted to the individual as much as possible according to the severity of the disease and the patient's response to therapy. <u>Coronary heart disease;</u> Long-term therapy, generally with a daily dose of 3 x 1 capsule Adalat. In some cases the dose can be increased in stages to 60 mg (3 x 2 capsules Adalat). For coronary spasms (Prinzmetal's angina, angina at rest) the daily dose can be temporarily increased to between 80 and a maximum of 120 mg (between 4 x 2 and 6 x 2 capsules Adalat) in individual cases. <u>Hypertension</u>: Daily dose: 3 x 10 to a maximum of 3 x 20 mg (3x 1 to 3 x 2 capsules) Adalat. If particularly rapid onset of action is required in cases of acute high blood pressure (hypertensive crissi) or impending angina perctoris attack, the individual dose is 1 - 2 capsules Adalat (10 - 20 mg) administered sublingually (the capsule should be bitten). In exceptional cases up to 3 capsules Adalat (30 mg). <u>Dosage interval</u>; Where the individual dose is 20 mg, the capsules should be taken at intervals of not less than 2 hours. <u>Interactions with other drugs;</u> Adalat/antihypertensive agents:

concomitant administration may enhance the antihypertensive effinifedipine. <u>Adalat/beta receptor blockers</u>; the patient must be mon carefully during concomitant administration since severe hypotension occur; development of heart failure has been reported occasionally. <u>Ad.</u> <u>cimetidine</u>; possible enhancement of antihypertensive effect. <u>Preser.</u> <u>tions</u>; Adalat: packs with 30, 50 and 100 capsules each containing 10 mg

nifedipine. Bayer AG, Leverkusen, West-Germany.

Co.-No.: 2 w

